Dietary macronutrient substrates in the intestinal lumen

Dietary macronutrient substrates in the intestinal lumen represent the primary energy-yielding components of the human diet—carbohydrates, proteins, and fats—as they undergo digestion and absorption within the gastrointestinal tract. These substrates are not therapeutic targets in the traditional sense, such as receptors or enzymes, but rather the molecules upon which these proteins act. Pharmacological strategies often focus on reducing the systemic uptake of these substrates to manage metabolic conditions like obesity and type 2 diabetes. For example, lipase inhibitors like orlistat prevent the hydrolysis of dietary fats, while alpha-glucosidase inhibitors like acarbose delay the breakdown of complex carbohydrates into absorbable sugars. Additionally, these substrates and their digestive products serve as ligands for nutrient-sensing G protein-coupled receptors (GPCRs) in the gut, which trigger the release of satiety-inducing and insulinotropic hormones. Consequently, the presence and processing of these luminal substrates are critical factors in metabolic health and the pathophysiology of malabsorption syndromes.

Other names

Dietary macronutrientsIntestinal nutrientsLuminal macronutrientsDietary fats, proteins, and carbohydratesIntestinal substrates

Drugs typically modulate the availability of these substrates by inhibiting the enzymes (e.g., pancreatic lipase, alpha-glucosidase) or transporters (e.g., NPC1L1) required for their digestion and absorption, or by acting as non-absorbable substitutes.